Skip to main content
. 2017 Jul 7;12(7):e0180497. doi: 10.1371/journal.pone.0180497

Table 4. Summary of testing of NPW specimens collected during phase II LAIV trial in Bangladesh (samples collected on days 2, 4 and 7 after vaccination).

Study group Type Subtype/
lineage
NPW specimens by
qRT-PCR (n = 287)
NPW specimens by sequencing (n = 2843)
N positive1 Ct value range N positive4 Vaccine-type Wild-type Inconclusive
LAIV A H1N1pdm 1 38.25 0 - - -
H3N2 138 21.90–39.96 134 133 0 1
Unsubtyped 0 - 65 6 0 0
B Yamagata 1962 20.27–41.18 0 - - -
Victoria 223 221 1 1
Placebo A H1N1pdm 0 - 0 - - -
H3N2 0 - 0 - - -
Unsubtyped 0 - 0 - - -
B Yamagata 72 20.90–38.86 6 0 6 0
Victoria 1 1 0 0

1co-infection with two viruses was detected in 55 subjects

2qRT-PCR protocol did not distinguish influenza B lineages

3Three NPW specimens positive by qRT- PCR (Ct values 34.50–42.66) were negative by RT-PCR

4co-infection with two or three viruses was detected in 86 subjects

5positive for H3/HA by qRT-PCR (Ct values 35.71–39.96).